Journal article
Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma
Abstract
BACKGROUND: Thymic stromal lymphopoietin (TSLP) is a key upstream regulator driving allergic inflammatory responses. We evaluated the efficacy and safety of ecleralimab, a potent inhaled neutralising antibody fragment against human TSLP, using allergen inhalation challenge (AIC) in subjects with mild atopic asthma.
METHODS: This was a 12-week, randomised, double-blind, placebo-controlled, parallel-design, multicentre allergen bronchoprovocation …
Authors
Gauvreau GM; Hohlfeld JM; FitzGerald JM; Boulet L-P; Cockcroft DW; Davis BE; Korn S; Kornmann O; Leigh R; Mayers I
Journal
European Respiratory Journal, Vol. 61, No. 3,
Publisher
European Respiratory Society (ERS)
Publication Date
March 2023
DOI
10.1183/13993003.01193-2022
ISSN
0903-1936